241 related articles for article (PubMed ID: 7152395)
1. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
Kogi K; Tanaka O; Kimura T; Saito T
Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacodynamic effects of the sustained-release tablet of isosorbide dinitrate and its bioavailability in conscious dogs (author's transl)].
Kogi K; Chida S; Kimura T; Saito T
Nihon Yakurigaku Zasshi; 1980 Mar; 76(2):99-107. PubMed ID: 7399370
[TBL] [Abstract][Full Text] [Related]
3. Contribution of isosorbide-5-mononitrate, a major metabolite of isosorbide dinitrate (ISDN), to the hemodynamic effect of ISDN administered orally in conscious dogs.
Kogi K; Satoh T
Jpn J Pharmacol; 1987 Jul; 44(3):249-57. PubMed ID: 3656782
[TBL] [Abstract][Full Text] [Related]
4. Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.
Kumagae H; Koiwaya Y; Tanaka K
Clin Ther; 1990; 12(1):31-43. PubMed ID: 2328526
[TBL] [Abstract][Full Text] [Related]
5. [Plasma levels of isosorbide dinitrate and its metabolites during intravenous infusion in surgical patients--effect of preoperative administration of isosorbide dinitrate].
Murakawa T; Hashimoto Y; Sato T; Takagi H; Kushikata T; Araki I; Kou H; Kimura F; Matsuki A
Masui; 1993 Feb; 42(2):225-32. PubMed ID: 8437354
[TBL] [Abstract][Full Text] [Related]
6. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
[TBL] [Abstract][Full Text] [Related]
7. Plasma disposition and hemodynamic effects of a single oral dose of isosorbide dinitrate in human males and females.
Nakatsu K; Brien JF; Savard G; Toffelmire EB; Abdollah H; Bennett BM; Marks GS
Biopharm Drug Dispos; 1992 Jul; 13(5):357-67. PubMed ID: 1498268
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of isosorbide dinitrate tape on exercise tolerance of patients with angina pectoris.
Saito M; Nobuyoshi M; Nakamura N; Nishiyama S; Haze K; Hiramori K; Ikeda M
Arzneimittelforschung; 1983; 33(9):1301-5. PubMed ID: 6685512
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
Keller-Stanislawski B; Marschner JP; Rietbrock N
Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374
[TBL] [Abstract][Full Text] [Related]
11. [Effects of isosorbide 5-mononitrate on cardiovascular function. (I). Effects on the left ventricular system].
Kogi K; Saito T
Nihon Yakurigaku Zasshi; 1985 May; 85(5):335-42. PubMed ID: 4029805
[TBL] [Abstract][Full Text] [Related]
12. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
Geigenberger A; Degen J; Maier-Lenz H
Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
[TBL] [Abstract][Full Text] [Related]
14. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system].
Menke G; Schnellhammer R; Rietbrock N
Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic effects of oral isosorbide-5-mononitrate and dinitrate in ischemic heart failure.
Rabinowitz B; Hod H; Chouraqui P; Rath S; Agranat O; Neufeld HN
Clin Cardiol; 1987 Oct; 10(10):603-8. PubMed ID: 3665218
[TBL] [Abstract][Full Text] [Related]
16. Effects of a sustained-release form of isosorbide dinitrate on left atrial pressure in dogs with experimentally induced mitral valve regurgitation.
Yamamoto Y; Suzuki S; Hamabe L; Aytemiz D; Huai-Che H; Kim S; Yoshiyuki R; Fukayama T; Fukushima R; Tanaka R
J Vet Intern Med; 2013; 27(6):1421-6. PubMed ID: 24010635
[TBL] [Abstract][Full Text] [Related]
17. [Assay of plasma isosorbide dinitrate and its metabolites after oral administration of immediate and delayed-action forms].
Audry E; Dallet P; Dubost JP; Langlois MH; Ernouf D; Narcisse G
Ann Pharm Fr; 1989; 47(4):235-41. PubMed ID: 2637644
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
[TBL] [Abstract][Full Text] [Related]
19. Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions.
Morrison RA; Fung HL
J Pharmacol Exp Ther; 1984 Oct; 231(1):124-30. PubMed ID: 6491969
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
Laufen H; Leitold M; Wildfeuer A
Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
